NCT07079631View on ClinicalTrials.gov

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

482

Participants

Timeline

Start Date

July 18, 2025

Primary Completion Date

December 31, 2030

Study Completion Date

May 31, 2031

Conditions
Metastatic Colorectal Cancer
Interventions
BIOLOGICAL

BNT314

Intravenous (IV) infusion

DRUG

BNT327

IV infusion

DRUG

SoC chemotherapy treatment 1

IV infusion / IV bolus

DRUG

SoC chemotherapy treatment 2

IV infusion / IV bolus / oral

DRUG

Bevacizumab

IV infusion

Trial Locations (1)

49546

RECRUITING

START Midwest, Grand Rapids

Sponsors

Lead Sponsor

BioNTech SE

Collaborators (1)

Genmab
All Listed Sponsors
collaborator

Genmab

INDUSTRY

lead

BioNTech SE

INDUSTRY

NCT07079631 - A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer | Biotech Hunter | Biotech Hunter